Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy–related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT
European Radiology · 2022-03 · 32 (3) · 1853-1865
DOI: 10.1007/s00330-021-08260-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Radiology, online erschienen am 18.09.2021. Verfasst von Enver Tahir und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Hospital Hamburg Eppendorf, Martinistr. 52, 20246, Hamburg, Ge…. Hauptthemen laut MEDLINE: Breast Neoplasms, Heart Diseases, Ventricular Dysfunction, Left. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Hamburg-Eppendorf (UKE).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
Cancer therapy-related cardiac dysfunction (CTRCD) is a relevant clinical problem and needs early prediction. This study aimed to analyze myocardial injury using serial laboratory and cardiac magnetic resonance imaging (CMR) parameters after epirubicin-based chemotherapy compared with left-sided radiotherapy and to study their value for early prediction of CTRCD.
Methods
Sixty-six consecutive women (53 ± 13 years) including n = 39 with epirubicin-based chemotherapy and n = 27 with left-sided radiotherapy were prospectively studied by 3 T CMR including left ventricular (LV) mass and volumes for ejection fraction (LVEF), as well as feature-tracking with global longitudinal strain (GLS) and T1/T2 mapping. CMR was performed at baseline, at therapy completion (follow-up 1, FU1), and after 13 ± 2 months (FU2). CTRCD was defined as LVEF decline of at least 10% to < 55% or a > 15% GLS change at FU2.
Results
T1 and T2 increased at FU1 after epirubicin-based chemotherapy, but not after left-sided radiotherapy. CTRCD occurred in 20% of patients after epirubicin-based chemotherapy and in 4% after left-sided radiotherapy. T1 at FU1 was the best single parameter to predict CTRCD with an area under the curve (AUC) of 0.712 (CI 0.587–0.816, p = 0.005) with excellent sensitivity (100%, 66–100%), but low specificity (44%, 31–58%). Combined use of increased T1 and LVEF ≤ 60% at FU1 improved AUC to 0.810 (0.695–0.896) resulting in good sensitivity (78%, 44–95%) and specificity (84%, 72–92%).
Conclusion
Only epirubicin-based chemotherapy, but not left-sided radiotherapy, resulted in increased T1/T2 myocardial relaxation times as a marker of myocardial injury. Combined use of CMR parameters may allow an early prediction of subsequent CTCRD. Key Points • Myocardial T1 and T2 relaxation times increased at FU1 after epirubicin-based chemotherapy, but not after left-sided radiotherapy. • Cancer therapy–related cardiac dysfunction (CTRCD) occurred in 20% of patients after epirubicin-based chemotherapy and in 4% after left-sided radiotherapy. • Combined use of increased T1 and reduced LVEF had an AUC of 0.810 (0.695–0.896) to predict CTRCD with good sensitivity (78%, 44–95%) and specificity (84%, 72–92%).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Hospital Hamburg Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. e.tahir@uke.de.
- Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Hospital Hamburg Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
- Department of Gynecology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- Department of Radiotherapy and Radio-Oncology, University Hospital Hamburg Eppendorf, Hamburg, Germany.
- Department of Oncology, Hematology and Bone Marrow Transplantation With the Section Pneumology, University Hospital Hamburg Eppendorf, Hamburg, Germany.
- Department of General and Interventional Cardiology, University Heart Center, Hamburg, Germany.
Förderung
- Universitätsklinikum Hamburg-Eppendorf (UKE)
Zitieren
APA
Tahir, E., Azar, M., Shihada, S., Seiffert, K., Goy, Y., Beitzen-Heineke, A., Molwitz, I., Muellerleile, K., Stehning, C., Schön, G., Adam, G., Petersen, C., Müller, V., & Lund, G. K. (2022). Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy–related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT. European Radiology, 32(3), 1853-1865. https://doi.org/10.1007/s00330-021-08260-7
Vancouver
Tahir E, Azar M, Shihada S, Seiffert K, Goy Y, Beitzen-Heineke A, et al. Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy–related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT. European Radiology. 2022;32(3):1853-1865. doi:10.1007/s00330-021-08260-7
BibTeX
@article{Tahir2022,
author = {Tahir, Enver and Azar, Manuella and Shihada, Sahar and Seiffert, Katharina and Goy, Yvonne and Beitzen-Heineke, Antonia and Molwitz, Isabel and Muellerleile, Kai and Stehning, Christian and Schön, Gerhard and Adam, Gerhard and Petersen, Cordula and Müller, Volkmar and Lund, Gunnar K},
title = {Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy–related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT},
journal = {European Radiology},
year = {2022},
volume = {32},
number = {3},
pages = {1853--1865},
doi = {10.1007/s00330-021-08260-7}
}
EUVIMED